603939.SH
益丰药房
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 23.65
−1.17%Year over year
Reported trailing growth
- Revenue
- +1.7%
- EBITDA
- —
- EBIT
- +11.9%
- EPS
- +9.8%
- Free cash flow
- -26.1%
- Operating cash flow
- -29.6%
Forward estimates
Based on analyst estimates
- Revenue
- +8.2%
- EBITDA
- +44.0%
- EPS
- +5.7%
Three-year CAGR
- Revenue
- +7.1%
- EBITDA
- +10.0%
- EBIT
- +9.2%
- Net income
- +10.0%
- EPS
- +3.1%
- Free cash flow
- -3.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026